Page 1

: sobi rare strength Progressing our pipeline April - June • Total revenue of SEK 3,211 M ( 3 070 ) , 5 per cent growth and 14 per cent at CER • EBITA¹ was SEK 922 M ( 1,018 ) , with an EBITA margin¹ of 29 per cent ( 33 ) • Earnings per share ( EPS ) before dilution of SEK 0.91 ( 0.96 ) • Haematology sales were SEK 2,125 M ( 2,037 ) , 12 per cent growth at CER • Sales for Elocta® were SEK 1,005 M ( 1,040 ) , 2 per cent growth at CER • Sales for Alprolix® were SEK 438 M ( 363 ) , 27 per cent growth at CER • Doptelet® grew by 42 per cent at CER to SEK 230 M • Immunology sales were SEK 752 M ( 714 ) , Gamifant® grew by 46 per cent at CER to SEK 168 M ( 132 ) • Cash flow from operating activities of SEK 1,393 M ( 1,942 ) January - June • Total revenue of SEK 6,872 M ( 7,709 ) , -11 per cent and -2 per cent at CER EBITA¹ was SEK 2,406 M ( 3,191 ) , with an EBITA margin¹ of 35 per cent ( 41 ) • EPS before dilution of SEK 3.27 ( 4.98 ) ● Haematology sales were SEK 4,003 M ( 4,431 ) , -3 per cent at CER • Sales for Elocta were SEK 1,861 M ( 2,399 ) , -18 per cent at CER • Sales for Alprolix were SEK 851 M ( 851 ) , 6 per cent growth at CER Doptelet grew by 88 per cent at CER to SEK 411 M ● 1 ● Immunology sales were SEK 2,305 M ( 2,514 ) , Gamifant grew by 47 per cent at CER to SEK 301 M ( 236 ) • Cash flow from operating activities of SEK 3,092 ( 3,828 ) Significant events after the reporting period • In July , Kineret® was submitted to EMA with a proposed indication for the treatment of coronavirus disease 2019 ( COVID - 19 ) in adult patients with pneumonia who are at risk of developing severe respiratory failure Outlook 2021 - unchanged • Revenue for the full - year 2021 is expected to be in the range of SEK 14,000-15,000 M • EBITA margin is expected to be in the range of 30-35 per cent of revenue Financial summary SEK M Total revenue Gross profit Gross margin¹ EBITA¹ EBITA adjusted ¹ , 2 EBITA margin¹ EBITA margin adjusted ¹ , 2 Profit for the period Earnings per share , before dilution , SEK Earnings per share , before dilution , SEK adjusted ¹2 1,2,3 Q2 2021 SOBI Q2 REPORT 2021 3,211 2,428 76 % 922 922 29 % 29 % 268 0.91 0.91 Q2 2020 3,070 2,381 78 % 1,018 1,018 33 % 33 % 283 0.96 0.96 Change 5 % 2 % -9 % -9 % -5 % -5 % -5 % Alternative Performance Measures ( APMs ) , see page 19 for further information . 2 EBITA 2020 excluding non - recurring items ; other operating income related to the reversal of the CVR liability of SEK 399 M. ³EPS full - year 2020 excluding the reversal of the CVR liability of SEK 399 M. Q2 2021 report H1 2021 6,872 5,363 78 % 2,406 2,406 35 % 35 % 964 3.27 3.27 Total revenue Q2 , SEK M 3,211 Revenue growth at CER , Q2 14 % EBITA margin¹ Q2 29 % H1 2020 Change 7,709 5,979 78 % 3,191 3,191 41 % 41 % 1,465 4.98 4.98 -11 % -10 % -25 % -25 % -34 % -34 % -34 % Full - year 2020 15,261 12,036 79 % 6,700 6,301 44 % 41 % 3,245 11.01 9.66